Recall Register

Drug recall: BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 100 mg, packaged in a) 60-count bottles (NDC 59746-315-60)…

Class III FDA enforcement event 76982. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.

Class III, in the words of FDA

a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences

Jubilant Cadista Pharmaceuticals, Inc. started this drug recall on 8 Apr 2016. The firm address in the FDA record is in Salisbury, MD. FDA put the recall in Class III. FDA event 76982 has 3 product records. The first FDA enforcement report date is 19 Apr 2017. The record gives the status Terminated, with the termination date 17 Apr 2017.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the USA

Recalling firm

Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

3 product records in the event.

FDA event 76982: product records
Recall numberProductQuantityClassStatusReport date
D-0669-2017BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 100 mg, packaged in a) 60-count bottles (NDC 59746-315-60) and b) 100-count bottles (NDC 59746-315-01), Rx only, Manufactured by: Julibant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.20,882 bottlesClass IIITerminated19 Apr 2017
D-0670-2017BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 150 mg, packaged in a) 60-count bottles (NDC 59746-316-60) and b) 100-count bottles (NDC 59746-316-01), Rx only, Manufactured by: Julibant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.81,077 bottlesClass IIITerminated19 Apr 2017
D-0671-2017BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, packaged in a) 60-count bottles (NDC 59746-317-60) and b) 100-count bottles (NDC 59746-317-01), Rx only, Manufactured by: Julibant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.19,682 bottlesClass IIITerminated19 Apr 2017

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class III: The lowest of the three FDA recall classes.

The event in context

Drug events that started in 2016
288
Share of these events in Class III
43%
Product records in this event
3Median of the firm: 1
Events of the firm on the register
25

Other events of the firm

Other FDA enforcement events of Jubilant Cadista Pharmaceuticals, Inc.
InitiatedProduct (first record)TypeClassRecords
27 Dec 2022Prochlorperazine Maleate Tablets, USP 5mg, 100 tablets, RX Only, Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MaryDrugClass III1
18 Jul 2022Irbesartan Tablets, USP, 150mg, 90- count bottles, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee- 247661, IndDrugClass II2
1 Apr 2022Methylprednisolone Tablets, USP 4mg, 100-count bottle, Rx Only, Manufactured by: Jubliant Cadista Pharmaceuticals Inc. SDrugClass III1
8 Mar 2022Meclizine Hydrochloride Tablets USP, 12.5 mg, packaged in a case of 24 bottles (100-count bottle), Rx only, ManufacturedDrugClass I1
20 Aug 2021Donepezil HCL Tablets, USP, 5 mg, 90-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd. India, Marketed by: DrugClass III1
1 Apr 2021Itraconazole Capsules, 100 mg, 30-count bottles, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee - 247661, IndDrugClass II1
19 Feb 2021Methylprednisolone Tablets USP, 4 MG, packaged in a 21-count blister pack, Rx only, Jubilant Cadista Pharmaceuticals, InDrugClass III1
6 Nov 2020clomiPRAMINE Hydrochloride Capsules USP, 50 mg, 30-count bottle, Rx Only, Manufactured by: Jubilant Cadista PharmaceuticDrugClass II1
26 Oct 2020Olanzapine Orally Disintegrating Tablets, 5 mg, 30 count (3x10 unit dose) blister pack, Rx only, Manufactured by: JubilaDrugClass III1
26 May 2020Lamotrigine Tablets, USP, 150 mg, 20,000-count bulk container, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., SDrugClass III1

Jubilant Cadista Pharmaceuticals, Inc.: all 25 events

Official channels

Cite this page

Recall Register. FDA enforcement event 76982. https://recallregister.com/fda/iii/76982/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the USA
What quantity of product is in FDA event 76982?
The event has 3 product records. The first record gives this quantity: 20,882 bottles
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2016 have the same class?
43% of the 288 drug events that started in 2016 are in Class III.